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Abstract
Background: For years, the genetics of metastatic colorectal cancer (CRC) have been studied using a variety of techniques.
However, most of the approaches employed so far have a relatively limited resolution which hampers detailed
characterization of the common recurrent chromosomal breakpoints as well as the identification of small regions carrying
genetic changes and the genes involved in them.
Methodology/Principal Findings: Here we applied 500K SNP arrays to map the most common chromosomal lesions
present at diagnosis in a series of 23 primary tumours from sporadic CRC patients who had developed liver metastasis.
Overall our results confirm that the genetic profile of metastatic CRC is defined by imbalanced gains of chromosomes 7, 8q,
11q, 13q, 20q and X together with losses of the 1p, 8p, 17p and 18q chromosome regions. In addition, SNP-array studies
allowed the identification of small (,1.3 Mb) and extensive/large (.1.5 Mb) altered DNA sequences, many of which contain
cancer genes known to be involved in CRC and the metastatic process. Detailed characterization of the breakpoint regions
for the altered chromosomes showed four recurrent breakpoints at chromosomes 1p12, 8p12, 17p11.2 and 20p12.1;
interestingly, the most frequently observed recurrent chromosomal breakpoint was localized at 17p11.2 and systematically
targeted the FAM27L gene, whose role in CRC deserves further investigations.
Conclusions/Significance: In summary, in the present study we provide a detailed map of the genetic abnormalities of
primary tumours from metastatic CRC patients, which confirm and extend on previous observations as regards the
identification of genes potentially involved in development of CRC and the metastatic process.
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Introduction
The development and progression of CRC is a multistep process
leading to the accumulation of genomic alterations that occur at
the single cell level over the lifetime of a tumour, from benign to
invasive and metastatic states leading to patient death [1,2]. For
many years, the genetics of metastatic CRC have been studied
with an increasingly high variety of techniques from conventional
cytogenetics [3] and fluorescence in situ hybridization (FISH) [4] to
comparative genomic hybridization (CGH) [5] and array CGH
(aCGH) [6]. Based on these techniques, many different recurrent
genetic abnormalities have been identified in metastatic CRC
which frequently include gains of chromosomes 8q, 13q and 20q
[7,8] together with losses of the 1p, 8p, 17p and 18q chromosomal
regions [9]. By contrast, detailed characterization of the common
breakpoint regions as well as the identification of the specific genes
targeted by such abnormalities has proven difficult with these
approaches. This is partially due to the fact that these techniques
have a relatively limited resolution which hampers identification of
the specific cancer-associated genes recurrently targeted in such
alterations. In fact, the highest resolution approaches applied so far
to the study of CRC are based on aCGH (i.e. Camps et al who
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13752applied a 185K oligonucleotide array with an estimated resolution
of 16 kb, to the analysis of 32 primary CRC tumours) [10].
In recent years, the availability of high-density single nucleotide
polymorphism (SNP) arrays has allowed identification of small
regions of chromosomal gains and losses with a much higher
resolution, down to 2.5 kb [11]. Thus, based on genome wide SNP
arrays, fine mapping of chromosomal breakpoints and subsequent
identification of the specific genes recurrently altered (deleted,
gained or amplified) is achieved for individual samples. This allows
for a more precise and detailed comparison of the breakpoint
regions found in different tumours and their correlation with the
clinical features of the disease.
In the present study we used 500K SNP mapping arrays with a
mean distance between interrogated SNPs of 5.8 kb (median
intermarker distance of 2.5 kb) to map genetic lesions present at
diagnosis in primary tumours from a group of 23 sporadic CRC
patients who developed liver metastasis. Our major goal was to
define the most frequent recurrent breakpoint regions in
metastatic CRC and the commonly gained and/or deleted genes
in the altered chromosomes. In order to evaluate the reproduc-
ibility of the SNP-array results we performed parallel interphase
FISH (iFISH) analyses of the same tumour samples using 24
probes directed against an identical number of regions from 20
different human chromosomes frequently altered in sporadic
CRC.
Materials and Methods
Patients and samples
Tissue specimens were obtained from primary tumours from 23
patients (15 males and 8 females; median age of 68 years, ranging
from 48 to 80 years) suffering from metastatic sporadic CRC. The
study was approved by the local ethics committee of the University
Hospital of Salamanca (Salamanca, Spain) and prior to entering to
the study, informed consent was given by each individual.
In each case, the diagnosis and the classification of the tumours
were performed according to the WHO criteria [12]. According to
tumour grade, 13 cases corresponded to well-differentiated CRC,
8 to moderately- and 2 to poorly-differentiated tumours.
Histopathological grade was confirmed in all cases in a second
independent evaluation by an experienced pathologist.
From the 23 primary tumors, 16 were localized at the right
(caecum, ascending or trasverse) or the left (descending and
sigmoid) colon and 7 in the rectum. Mean size of primary tumors
was of 5.261.8 cm with the following distribution according to the
TNM stage [13]: T3N0M1, 3 cases; T3N1M1, 9; T3N2M1, 3;
T4N0M1, 5; T4N1M1, 1 and; T4N2M1, 2 patients. In all cases
paired liver metastases were identified either at the time of
colorectal surgery (n=14) or during the first year after initial
diagnosis (n=9); the mean size of the largest liver metastases/
patient was of 5.362.8 cm (range: 2 to 10 cm).
After histopathological diagnosis was established, samples from
representative areas of the primary tumours showing macrosco-
pical infiltration, were used to prepare single cell suspensions to be
stored (220uC) in methanol/acetic (3/1; vol/vol) for further
iFISH analyses [14]. The remaining tissue was either fixed in
formalin and embedded in paraffin or frozen in liquid nitrogen,
and stored at room temperature (RT) and at 280uC, respectively.
From the paraffin-embedded tissue samples, sections were cut
from three different areas representative of the tumoural tissue
used to prepare single cell suspensions and placed over poly L-
lysine coated slides. All tissues were evaluated after hematoxylin-
eosin staining to confirm the presence of tumour cells and evaluate
their quantity in samples to be studied by both iFISH and SNP-
arrays. For SNP-array studies, tumour DNA was extracted from
freshly-frozen tumour tissues mirror cut to those used for iFISH
analyses which contained $65% epithelial tumour cells. In turn,
normal DNA was extracted from matched peripheral blood (PB)
leucocytes from the same patient. For both types of samples
(tumour tissue and PB leucocytes), DNA was extracted using the
QIAamp DNA mini kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions.
Analysis of single nucleotide polymorphism (SNP) arrays
Paired samples of purified tumoural DNA and normal PB DNA
from individual patients were hybridized to two 250K Affymetrix
SNP Mapping arrays (NspI and StyI SNP arrays, Affymetrix, Santa
Clara, CA) using a total of 250 ng of DNA per array, according to
the instructions of the manufacturer. Fluorescence signals were
detected using the GeneChip Scanner 3000 (Affymetrix). Average
genotyping call rates of 94.4% and 97.3% were obtained for
tumoral and paired normal PB DNA samples, respectively. Only
those SNPs with a call rate $92.3% were used for further analyses.
In order to calculate genome-wide copy number (CN) changes
in tumoural vs. normal samples, the aroma.affymetrix algorithm was
used, following the CRMA v2 method, as described elsewhere (R-
software package, Berkeley, CA) [15]. The following sequential
steps were used for this purpose: i) calibration for crosstalks
between pairs of allele probes; ii) normalization for probe
nucleotide-sequence effects, and; iii) normalization for PCR
fragment length- and probe localization-dependent effects. Then,
data derived from both the 250K StyI and the 250K NspI arrays
was integrated into a single database and raw CN values
calculated as transformed log2 values of the tumoural/normal
ratio obtained for paired SNP fluorescence signals.
Log2 ratio values were then used to identify DNA regions which
showed similar CN values, using the Circular Binary Segmenta-
tion (CBS) algorithm [16]. For the identification of altered (gained
or lost) DNA regions, a threshold was established based on the
changes observed in the log2 CN values (fluorescence intensity
ratio) of sequential tumour DNA segments found for each
individual. Therefore, log2 ratio .0.09 and ,20.09 were used
as cut-off thresholds to define the presence of increased and
decreased CN values, respectively. High-level gains (amplifica-
tions) were defined as regions with a mean log2 CN ratio $0.22
for $3 contiguous SNPs. The specific frequencies of both CN
gains and losses per SNP were established and plotted along
individual chromosomes for each individual case analyzed.
Minimal common regions (MCR) of gain and loss were defined
as the smallest group of contiguous SNPs ($3) with a high
frequency of gains and losses (Z-score threshold $2.1) according to
the overall distribution of CN values found in the entire tumour
cell genome, respectively. Common recurrent breakpoint regions
were defined as those chromosomal regions which recurrently
showed transition from one CN state (gain, loss or no-change) to
another for the whole set of individual samples analyzed, at a
frequency of $35% of the cases (n=8/23 samples).
Interphase fluorescence in situ hybridization (iFISH)
studies
In all cases, iFISH studies were performed on an aliquot of the
single cell suspension prepared from the tumour sample. A set of
24 locus-specific FISH probes directed against DNA sequences
localized in 20 different human chromosomes, specific for those
chromosomal regions more frequently gained or deleted in
sporadic CRC [4,6,8,17,18] were systematically used to validate
the results obtained with the SNP arrays (Table 1).
Genetics of Colorectal Cancer
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been previously described in detail [19]. Briefly, dried slides
containing both the tumour cells’ and the probes’ DNA were
denatured (1 min at 75uC) and hybridized overnight (37uC) in a
Hybrite termocycler (Vysis Inc, Downers Grove, IL, USA). After
this incubation, slides were sequentially washed (5 min at 46uC) in
50% formamide in a 26saline sodium citrate buffer (SSC) and in
2XSSC. Finally, nuclei were counterstained with 35 mLo fa
mounting medium containing 75 ng/ml of 4,6-diamidino 2-
phenylindole (DAPI; Sigma, St Louis, MO, USA); Vectashield
(Vector Laboratories Inc, Burlingame, CA, USA) was used as
antifading agent.
A BX60 fluorescence microscope (Olympus, Hamburg, Ger-
many) equipped with a 1006oil objective was used to count the
number of hybridization spots/nuclei for $200 cells/sample. Only
those spots with a similar size, intensity and shape were counted in
areas with ,1% unhybridized cells; doublet signals were
considered as single spots. A tumour was considered to carry a
numerical abnormality for a given chromosomal region when the
proportion of cells displaying an abnormal number of hybridiza-
tion spots for the corresponding probe was at a percentage higher
or lower than the mean value plus two standard deviations (SD) of
the mean percentage obtained with the same probe in control
samples (n=10).
Quantitative Real-Time PCR
In order to validate the results obtained in the SNP-array
studies, quantitative real-time polymerase chain reaction (RQ-
PCR) was performed using the Step One Plus Real-Time PCR
System (Applied Biosystems, Foster City, CA) in matched normal
and tumoural samples in 18/23 cases. Expression of the MAP2K4,
MYC and BIRC7 genes was analyzed. We employed TaqManH
Gene Expression Assays designed by Applied Biosystems (Applied
Biosystems, Foster City, CA) according to the manufacturers
instructions, and the assays ID for the genes studied were as
follows: Hs_00387426-m1 (MAP2K4), Hs_00153408-m1 (MYC)
and Hs_00223384-m1 (BIRC7).
Each PCR was carried out in duplicate in a 10 uL volume
using the TaqManH Fast Universal Mastermix (Applied Biosys-
tems) and the following cycling parameters: incubation at 95uC
(20 sec), followed by 50 cycles at 95uC (1 sec) and an incubation
at 60uC (20 sec). Analysis was made using StepOne software v2.0.
The obtained data were normalized by using the internal
housekeeping gene, GAPDH. Relative quantification was calcu-
lated using the equation 2
2DCT=C TGENE-CTGAPDH. The final
mRNA expression index in each sample was calculated as follows
(arbitrary units; AU): mRNA expression index = MYC or
MAP2K4 or BIRC7 mRNA value/ GAPDH mRNA value X
10,000 AU.
Table 1. A panel of 24 locus-specific FISH probes directed against 24 different regions localized in 20 different human
chromosomes were used to validate the results obtained with the SNP arrays.
iFISH probe chromosome
localization iFISH probe length (kb) Target gene
N. of SNPs inside the region identified by the iFISH
probe
1p36 110 P58 120
1q25 620 ABL2 68
2p24 200 NMYC 38
3q26 839 HTERC 52
5p15.2 450 D5S721 118
6q23 740 MYB 88
7q31 200 D7S486 33
8p22 170 LPL 39
8q24 600 CMYC 159
9p21 190 P16 37
9q34 270 ABL1 33
10q23 370 PTEN 49
11q22 184 ATM 69
12p13 350 TEL 98
13q14 220 RB1 14
13q34 550 LAMP1 92
14q32 1500 IGH 82
15q22 540 DAPK2 38
17p13 145 TP53 12
18q21 750 BCL2 153
19q13 340 CD37 21
20q13.2 320 ZNF217 53
21q22 500 AML1 111
22q11.2 300 BCR 36
All probes were purchased from Vysis Inc (Chicago, IL, USA), except for the 3q26, 15p22 and 19q13 probes, which were obtained from QBIOgene Inc (Amsterdam, The
Netherlands).
doi:10.1371/journal.pone.0013752.t001
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PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13752Figure 1. Metastatic colorectal cancer genome for the 23 CRC patients studied. In panel A an overall view of both the gained (blue areas)
and lost (red areas) chromosome regions across the genome are shown for the 23 patients genotyped on the Affymetrix 500k SNP array platform. In
panel B a summary plot showing the frequency of CN gains (plotted above zero values in the x-axis) and losses (plotted below zero values the x-axis)
detected for each individual chromosome, is displayed. Those chromosome regions most frequently showing recurrent losses and gains by SNP
Genetics of Colorectal Cancer
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For all continuous variables, mean values (and SD) and range
were calculated using the SPSS software package (SPSS 12.0 Inc,
Chicago, IL USA); for dichotomic variables, frequencies were
reported. In order to evaluate the statistical significance of
differences observed between groups, the Mann-Whitney U and
X
2 tests were used for continuous and categorical variables,
respectively (SPSS).
A multivariate stepwise regression analysis (regression, SPSS)
was performed to determine the correlation between the structural
and/or numerical abnormalities found for both iFISH, SNP-array
techniques and their relationship with the expression of those
genes analyzed by RQ-PCR. Only those iFISH probes with $12
SNPs localized in the iFISH mapped region (Table 1) were used
for correlation studies with the CN status identified by the SNP
array (gain vs. loss vs. no change) for those SNPs localized at each
iFISH region. P-values ,.01 were considered to be associated with
statistical significance.
Results
Map of CN changes by SNP arrays
Overall CN changes for at least one chromosomal region were
detected in all 23 tumors studied. The highest frequency of CN
losses detected corresponded to chromosomes 1p (n=17; 74%), 8p
(n=18; 78%), 14q (n=15; 65%), 17p (n=19; 83%), 18 (n=21;
91%) and 22q (n=17; 74%); in turn, CN gains more frequently
involved chromosomes 1q (n= 10; 43%), 7 (n=20; 87%), 8q
(n=17; 74%), 13q (n=18; 78%), 20q (n=20; 87%) and X (n=13;
57%) (Figure 1); these (gained) chromosomes/chromosomal
regions also revealed the highest level of genomic amplification
(Table S1). In addition, gains and losses of many other
chromosomal regions were identified at lower frequencies
(Figure 1). An illustrating map of the most frequently gained/lost
chromosome regions according to SNP-array studies, is shown in
figure 2.
Of note, SNP arrays allowed the identification of 43 small DNA
sequences (arbitrarily defined as regions of ,1300 kb) which
displayed recurrent CN changes (gains and losses). Interestingly,
most of those regions which showed recurrent CN changes
(n=28/43) contained at least one known well-characterized gene,
five contained known cancer-associated genes and one region held
a microRNA gene (MIR1208), localized at chromosome 8q24.21
(Table 2). The exact number of small regions characterized by CN
changes, as well as the relative proportion of CN gains vs. losses
varied widely among the different chromosomes. The 43 small
regions containing CN gains and losses were coded in those
chromosomes more frequently affected by CN changes and their
arrays were localized in chromosomes 1p, 8p, 17p and 18, and involved the whole chromosome 7 and the 8q, 13q and 20q chromosome regions,
respectively.
doi:10.1371/journal.pone.0013752.g001
Figure 2. Representative karyotype of a primary metastatic colorectal tumor as determined by the Affymetrix 500K SNP array
genotyping platform, showing summary results for those chromosome gains/losses more frequently detected in the colorectal
tumor samples analyzed (n=23).
doi:10.1371/journal.pone.0013752.g002
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8q, 16; 13q, 7; 17p, 3; 18q, 4; 20q, 3, and; Xq, 2 region. In
addition, other regions carrying recurrent large-scale CN gains
and losses (arbitrarily defined as regions of .1500 kb) were
identified at the 8q21.13, 17p12, 17p11.2, 22q13 and Xq25
chromosome segments (one in each chromosome). Interestingly,
Table 2. Most frequently detected small regions (,1300 kb) of gain and loss in primary sporadic colorectal tumors genotyped on
the Affymetrix 500K SNP array platform (n=23).
Minimal common altered
regions (bp)
Region length
(bp) N. of SNPs
Chromosome
band Event
% of altered
cases Gene list
Chr 1: 26,131,131-26,191,419 60,288 16 1p36.11 Deletion 74 PAFAH2
Chr 7: 8,255,230-8,280,496 25,266 10 7p21.3 Gain 74 ICA1
Chr 7: 10,461,770-10,486,412 24,642 8 7p21.3 Gain 74 –
Chr 7: 12,514,442-12,576,898 62,456 9 7p21.3 Gain 74 SCIN
Chr 8: 32,105,734-32,675,812 570,078 196 8p12 Deletion 70 –
Chr 8: 198,834-392,556 193,722 46 8p23.3 Deletion 70 FAM87A, FBXO25
Chr 8: 400,640-539,716 139,076 29 8p23.3 Deletion 70 C8orf42
Chr 8: 23,264,737-23,277,681 12,944 8 8p21.3 Deletion 70 –
Chr 8: 86,214,670-86,946,337 731,667 52 8q21.2 Gain 65 LRRCC1, E2F5, CA13, CA1, CA3, CA2
Chr 8: 87,377,186-87,789,535 412,349 65 8q21.3 Gain 65 WWP1, FAM82B, CPNE3, CNGB3
Chr 8: 88,872,540-89,066,702 194,162 24 8q21.3 Gain 65 WDR21C
Chr 8: 91,462,487-91,474,759 12,272 2 8q21.3 Gain 65 –
Chr 8: 91,686,333-91,735,940 49,607 10 8q21.3 Gain 65 TMEM64
Chr 8: 94,759,374-95,077,320 317,946 44 8q22.1 Gain 65 RBM12B, C8orf39, TMEM67, PPM2C
Chr 8: 95,294,349-95,435,061 140,712 28 8q22.1 Gain 65 GEM
Chr 8: 95,593,385-95,776,644 183,259 36 8q22.1 Gain 65 KIAA1429, RBM35A
Chr 8: 128,638,191-128,724,583 86,392 25 8q24.21 Gain 65 –
Chr 8: 129,180,096-129,268,067 87,971 43 8q24.21 Gain 65 MIR1208
Chr 8: 130,906,244-131,222,249 316,005 35 8q24.21 Gain 65 FAM49B
Chr 8: 133,845,345-133,868,639 23,294 9 8q24.22 Gain 65 PHF20L1
Chr 8: 133,882,656-133,900,665 18,009 6 8q24.22 Gain 65 –
Chr 8: 135,527,585-135,836,235 308,650 97 8q24.22 Gain 65 ZFAT
Chr 8: 136,498,075-136,866,133 368,058 74 8q24.23 Gain 65 KHDRBS3
Chr 8: 137,055,200-137,091,177 35,977 12 8q24.23 Gain 65 –
Chr 13: 73,603,130-73,627,939 24,809 10 13q22.1 Gain 78 KLF12
Chr 13: 74,972,248-75,117,835 145,587 26 13q22.2 Gain 78 COMMD6, UCHL3, LMO7
Chr 13: 75,689,304-75,689,865 561 2 13q22.2 Gain 78 –
Chr 13: 76,352,482-76,366,765 14,283 11 13q22.3 Gain 78 KCTD12
Chr 13: 78,098,212-78,143,588 45,376 7 13q31.1 Gain 78 C13orf7
Chr 13: 78,805,700-79,077,299 271,599 46 13q31.1 Gain 78 RBM26, NDFIP2
Chr 13: 79,621,013-79,845,948 224,935 40 13q31.1 Gain 78 SPRY2
Chr 17: 10,693,238-11,021,844 328,606 89 17p13.1 Deletion 78 –
Chr 17: 14,234,746-14,967,525 732,779 214 17p12 Deletion 78 –
Chr 17: 14,984,724-15,082,587 97,863 18 17p12 Deletion 78 PMP22
Chr 18: 41,130,655-41,494,986 364,331 134 18q12.3 Deletion 91 SLC14A2
Chr 18: 45,410,728-45,497,910 87,182 29 18q21.11 Deletion 91 –
Chr 18: 45,654,114-46,036,475 382,361 144 18q21.11 Deletion 91 MYO5B, CCDC11
Chr 18: 46,252,199-46,288,353 36,154 12 18q21.11 Deletion 91 –
Chr 20: 37,766,095-38,339,016 572,921 131 20q12 Gain 83 HSPEP1
Chr 20: 51,012,908-51,013,194 286 2 20q13.2 Gain 83 –
Chr 20: 52,991,500-54,234,439 1,242,939 325 20q13.2 Gain 83 CBLN4
Chr X: 134,159,698-134,160,254 556 2 Xq26.3 Gain 57 –
Chr X: 151,650,011-151,652,710 2699 2 Xq28 Gain 57 –
Genes which have been associated with cancer are shown in bold.
doi:10.1371/journal.pone.0013752.t002
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malignancy and contained genes i) relevant to the metastatic
process (i.e.: TPD52, FABP5, MAP2K4, LLGL1, TOP3A,
ALDH3A2, UPK3A, FBLN1, TYMP), ii) associated with intracellu-
lar signaling processes (i.e.: PAG1, ELAC2, RASD1 and
TNFRSF13B) and iii) genes involved in the regulation of the cell
cycle (i.e.: FLCN, PEMT and XIAP); in turn, three of these large
CN regions showing CN losses and one with CN gains contained a
total of 8 known microRNAs (Table 3).
Chromosomal regions showing high-level CN gains
The highest levels of genetic amplification were detected for the
7p15.2, 8q24.21, 13q12.13 and 20p12.3 chromosome bands with
maximum fluorescence intensity log2 ratios of 0.99 (0.2360.11),
1.45 (0.3560.15), 1.47 (0.3160.22) and 0.96 (0.2860.11), respec-
tively (Table 4). Several genes which are potentially involved in the
pathogenesis of CRC are localized in these four chromosomal
regions. Among others, these include the CYCS and UPP1 genes on
chromosome 7p, the MYC gene at chromosome 8q24.21, the
HSPH1 and CDX2 genes at chromosome 13q and the CDC25B,
PLCB4, TNFRSF6B, OGFR, NTSR1, CDH4, CYP24A1 and RGS19
genes in chromosome 20. The most commonly amplified single
region (18/23 cases; 78%) corresponded to a region localized at
chromosome 20q11.22 identified by the SNP_A-2220183 and the
SNP_A-2039695 at the 33,776,127 bp and 33,954,944 bp posi-
tions, respectively (Table S1).
Interestingly, we recorded a statistically significant association
between tumour grade and presence of gains/amplifications at the
20p13 chromosomal region localized between the 2,574,587 and
2,993,797 bp positions and assessed by 66 SNPs with a greater
frequency of well- vs moderately-differentiated tumours- (11/13
(85%) vs 2/8 (25%); p=0.005) among cases with this chromo-
somal alteration.
Recurrent chromosomal breakpoints identified by SNP-
arrays
Based on the analysis of the distribution of chromosomal
breakpoints defined by the SNP-arrays, four recurrent chromo-
somal breakpoints (arbitrarily defined as DNA segments showing
CN changes in more than one third of the cases) were identified at
chromosomes 1p12, 8p12, 17p11.2 and 20p12.1 (Figure S1).
Chromosomes 1, 8 and 20 showed a high number (.145) of
different breakpoint regions with a variable and heterogeneous
distribution; in contrast, a highly prevalent breakpoint region was
identified in the centromeric portion of chromosome 17p, between
the genome coordinates 20,156,497 bp and 22,975,771 bp (15/19
patients with abnormalities for this chromosome), and a minimum
size of 28.2 Mb for the recurrent breakpoint. In these 15 cases, the
first gene affected on the retained telomeric side of the breakpoint
region was the CYTSB gene and the first constantly deleted gene
on the centromeric side was the FAM27L gene. Interestingly, in 13
of these 15 patients a preferential breakpoint occurred at the
21,769,828–22,975,771 genome coordinate where the FAM27L
gene is coded.
Correlation between the chromosomal changes detected
by SNP-arrays and both iFISH and RQ-PCR studies
In order to evaluate the consistency of the chromosomal
changes identified by the SNP-arrays, iFISH analysis were
performed in parallel for a total of 24 chromosome regions from
20 different chromosomes. Overall our results showed a high
degree of correlation (mean r
2 of 0.73602; range: 0.65 to 0.91)
between both methods, including when such analysis was
restricted to the most frequently altered regions (r
2$0.67)
(Table 5).
In order to assess the impact of the information generated by
SNP arrays, the expression of three genes (MAP2K4, MYC and
Table 3. Most frequently detected extensively altered chromosome regions with CN changes (.1500 kb) in primary sporadic
colorectal tumors genotyped on the Affymetrix 500K SNP array platform (n=23).
Extensively altered
regions (bp)
Region length
(bp)
Chromosome
band Event
% of altered
cases Gene list
Chr 8: 80,831,670-82,390,493 1,558,823 8q21.13 Gain 65 HEY1, MRPS28, TPD52, ZBTB10, ZNF704, PAG1, FABP5
Chr 17: 11,135,229-14,009,355 2,874,126 17p12 Deletion 78 DNAH9, ZNF18, MAP2K4, MIR744, MYOCD, ELAC2,
HS3ST3A1, MIR548H3, COX10
Chr 17: 16,270,540-19,616,367 3,345,827 17p11.2 Deletion 78 TRPV2, C17orf45, C17orf76, ZNF287, ZNF624,
CCDC144A,TNFRSF13B, C17orf84, FLCN, COPS3, NT5M,
MED9, RASD1, PEMT, RAI1, SREBF1, MIR33B, TOM1L2,
LRRC48, ATPAF2, C17orf39, DRG2, MYO15A, ALKBH5,
LLGL1, FLII, SMCR7, TOP3A, SMCR8, SHMT1, NOS2B,
TBC1D28, TRIM16L, FBXW10, FAM18B, PRPSAP2, SLC5A10,
FAM83G, GRAP, EPN2, B9D1, MIR1180, MAPK7, MFAP4,
ZNF179, SLC47A1, ALDH3A2, SLC47A2, ALDH3A1, ULK2
Chr 22: 43,616,234-49,576,671 5,960,437 22q13 Deletion 57 ARHGAP8, PHF21B, NUP50, C22orf9, MIR1249, UPK3A,
FAM118A, SMC1B, RIBC2, FBLN1, ATXN10, WNT7B,
C22orf26, MIRLET7A3, MIRLET7B, PPARA, PKDREJ, GTSE1,
TRMU, CELSR1, GRAMD4, CERK, TBC1D22A, FAM19A5,
C22orf34, BRD1, ZBED4, ALG12, CRELD2, PIM3, IL17REL,
TTLL8, MLC1, MOV10L1, PANX2, TRABD, TUBGCP6,
HDAC10, MAPK12, MAPK11, PLXNB2, FAM116B, SAPS2,
SBF1, ADM2, MIOX, TMEM112B, NCAPH2, SCO2, TYMP,
KLHDC7B, CPT1B, CHKB, MAPK8IP2, ARSA,SHANK3, ACR,
RABL2B
Chr X: 120,721,375-126,726,076 6,004,701 Xq25 Gain 57 GRIA3, THOC2, MIR220A, XIAP, STAG2, SH2D1A, ODZ1,
WDR40C, WDR40B, CXorf64
Genes which have been associated with cancer are shown in bold.
doi:10.1371/journal.pone.0013752.t003
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from the SNP-array data, the MYC and BIRC7 relative transcript
levels were up-regulated in 15/18 (83%) and 14/18 (78%) tumours
analyzed, respectively. Conversely, the MAP2K4 gene was down-
regulated in 16/18 (89%) tumours (Figure 3). Upon comparing the
results obtained with the two methods, a significant (p,0.001)
correlation was observed between the microarray data and the
expression of the three genes evaluated by RQ-PCR techniques
with correlation coefficients (r
2) of 0.88, 0.66 and 0.64 for
MAP2K4, MYC and BIRC7 genes, respectively.
Discussion
In this study we describe a comprehensive map of the genetic
abnormalities present in primary tumors from metastatic CRC
through the usage of high-resolution 500K SNP arrays. To our
knowledge this is the most extensive study using high-resolution
SNP-arrays to define the genetic alterations in this subgroup of
CRC patients. Overall, our results confirm previous analyses using
chromosome banding techniques [20], CGH [5], SKY [21],
aCGH [6,10] and low-resolution 50k SNP-arrays [22].
Previous reports in which similar SNP-array tools have been
applied to investigate the genetic profile of non-metastatic CRC
[23] have shown in a subset of patients with advanced carcinomas
in the absence of liver metastases (n=18), a relatively low
frequency of 1p, 8p, 9q, 14 and 17p losses and unique
amplifications at chromosome 20q. Interestingly, among our series
of metastatic CRC patients the frequency of losses at the same
chromosomal regions was strikingly higher: 1p, 74% vs 11%; 8p,
78% vs 33%; 9q, 35% vs 6%; 14, 65% vs 39%; and; 17p, 83% vs
33%. In turn, we also detected additional amplifications at 7p, 8q
and 13q, as well as at the 20q chromosomal region. In line with
our observations, Al-Mulla et al [24] also found that, once
compared to patients without metastatic disease (n=30) CRC
patients with liver metastases (n=26) more frequently displayed
losses of chromosomes 1p, 4, 5q, 8p, 9p, and 14q. Altogether,
those results indicate that the genetic profile of metastatic CRC is
defined by imbalanced gains/amplifications of chromosomes 7p,
8q, 13q and 20q together with losses of the 1p, 8p, 9p, 14q and
17p chromosomal regions [5,20,25–27]. In addition, here we
describe new recurrently altered regions that contain cancer genes,
many of which have been previously involved in the pathogenesis
of CRC, at the same time, we provide detailed characterization of
recurrent chromosomal breakpoints most frequently occurring in
primary tumours from CRC patients who had developed liver
metastases.
Interestingly, a relatively high degree of correlation was found
between the cytogenetic alterations detected by SNP-arrays and
iFISH studies. Despite this, slight differences were noted between
both techniques. On one hand, these were due to the lower
Table 4. Most frequently detected high-level amplified chromosome regions (average log2 copy number ratio $0.22) containing
genes commonly associated with cancer in primary sporadic colorectal tumors genotyped on the Affymetrix 500K SNP array
platform (n=23).
Amplified chromosome regions (bp)
Chromosome
band
Mean Log2
Ratio
Maximum Log2
Ratio
% of altered
cases Cancer associated genes
Chr 7: 21,060,948-21,773,238 7p15.3 0.22 0.51 57 SP4
Chr 7: 25,072,457-29,780,614 7p15.2 0.23 0.99 52 CYCS, CHN2, JAZF1, HOXA1,
HOXA4, HOXA5, HOXA7, HOXA9,
HOXA10, HOXA11, HNRPA2B1
Chr 7: 30,433,934-47,043,330 7p15.1 0.24 0.69 52 SFRP4, AMPH, RALA, INHBA,
PPIA, IGFBP3
Chr 7: 47,249,414-48,538,115 7p12.3 0.23 0.51 57 UPP1
Chr 7: 50,305,027-50,512,587 7p12.2 0.24 0.51 61 DDC, IKZF1
Chr 8: 128,130,968-129,218,353 8q24.21 0.35 1.45 61 MYC
Chr 13: 22,371,210-23,251,245 13q12.12 0.29 0.81 57 SACS
Chr 13: 23,722,973-24,224,179 13q12.12 0.30 0.90 57 ATP12A, PARP4
Chr 13: 25,516,360-33,070,797 13q12.13 0.31 1.47 61 BRCA2, RXFP2, HMGB1, HSPH1,
SLC7A1, FLT1, FLT3, CDX2, PDX1,
GTF3A
Chr 20: 3,590,646-3,775,309 20p13 0.28 0.62 52 CDC25B, SIGLEC1, GFRA4
Chr 20: 6,077,268-10,228,083 20p12.3 0.28 0.96 52 PLCB4, PLCB1
Chr 20: 33,776,127-33,954,944 20q11.22 0.27 0.51 78 RBM39, PHF20
Chr 20: 47,898,202-49,082,996 20q13.13 0.27 0.55 74 ADNP, BCAS4, PTPN1, CEBPB,
SNAI1
Chr 20: 52,203,846-52,261,791 20q13.2 0.27 0.55 74 CYP24A1
Chr 20: 59,237,873-59,740,719 20q13.33 0.27 0.59 74 CDH4
Chr 20: 59,926,031-62,297,793 20q13.33 0.28 0.82 74 TAF4, SS18L1, LAMA5, GATA5,
SLCO4A1, NTSR1, OGFR, TCFL5,
DIDO1, BIRC7, EEF1A2, PTK6,
STMN3, NFRSF6B, TPD52L2,
SOX18, RGS19, OPRL1,
Genes which have been commonly associated with colorectal cancer are shown in bold.
Only those regions with recurrently amplified DNA copy-number found in at least half of the cases, are listed.
doi:10.1371/journal.pone.0013752.t004
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chromosomal abnormalities present in only a small proportion of
all cells in the sample (i.e. secondary genetic lesions absent in the
ancestral tumour cell clones) [28]. On the other hand, they were
attributable to the increased sensitivity of the SNP-array vs. iFISH
studies as regards identification of small interstitial changes [11].
In this regard, our results show occurrence of a high number of
CN changes involving minimal/small regions (,1.3 Mb) and to a
less extent, also extensive/large (.1.5 Mb) regions which
frequently went undetectable by iFISH. Interestingly, several of
these small and large altered regions contain cancer-associated
genes known to be involved in CRC and/or the metastatic
process: i.e. the TPD52 [29], FABP5 [30], MAP2K4 [31], LLGL1
[32], FBLN1 [33] and TYMP [34] genes.
Among all human chromosomes, chromosomes 17 and 18 were
those more frequently found to be altered in our series, their
abnormalities typically consisting on extensive deletions involving
the TP53 and DCC genes, respectively, in addition to other tumor
suppressor genes, such as MAP2K4 at 17p12. A potential role for
chromosome 18q in the development of CRC with associated liver
metastases has been previously reported [35]; in this regard,
decreased expression of Smad4 in addition to DCC, has been
pointed out as a potential target protein coded in chromosome 18q
since it is associated with both liver and lymph node metastases
[36]. In line with these findings we also identified loss of the
SMAD4 gene in the great majority (83%) of the metastatic cases
analyzed. By contrast, the most frequently (78% of cases) amplified
region was found in chromosome 20, at 20q11.22. This is a
relatively small region of 178,817 bp which harbors 8 known
genes, half of which have been associated with CRC: TNFRSF6B
[37], OGFR [38], NTSR1 [39] and CDH4 [40]. Among these
genes, overexpression of TNFRSF6B -a gene that belongs to the
tumor necrosis factor receptor (TNFR) super-family- has been
reported in advanced stages of CRC [37] and other tumors of the
gastrointestinal tract [41], in association with an increased
resistance to adjuvant chemotherapy [42]; in turn, increased
NTSR1 expression has been reported as an early event in colon
tumorigenesis that contributes to tumor progression and an
aggressive clinical behavior [39]. Similarly, we also identified
amplification and overexpression of the MYC gene at 8q24 in the
great majority of the primary tumors, which have both been
previously suggested to be involved in disease progression to a
metastatic tumour [28;43].
From the clinical point of view, gain/amplification of 20p13 was
associated with a higher frequency of well vs. moderately-
differentiated tumours. Noteworthy, this chromosomal region
contains genes which have been previously associated with disease
progression. Accordingly, Miyoshi N et al have recently suggested
that overexpression of the TGM2 gene in CRC patients is
associated with a shorter overall survival [44] and expression of the
PTPRA gene has been recurrently associated with progression of
gastric cancer, including lymphovascular invasion and liver/
peritoneal dissemination [45,46].
Apart from defining the most frequently altered genes in
metastatic CRC, this study was also aimed at detailed character-
ization of the most frequent recurrent breakpoint regions
associated with such genetic changes. The number of different
breakpoints detected within individual chromosomes is usually
considered as a surrogate marker for chromosomal instability in
cancer. In the present study, we found 245 different breakpoints
for chromosome 1. This frequency is significantly higher than that
reported by others using aCGH analyses of CRC without distant
metastases: 16 different chromosomes breakpoints found, in a
group of 32 patients [10]. These results suggest that advanced-
stage and metastatic CRC could be associated with a greater
number of breakpoints and higher chromosomal instability. In line
with this hypothesis, Knutsen et al [21] found 407 chromosomal
breakpoints in 15 CRC cell lines, using spectral karyotyping with a
high frequency of recurrent breakpoints in the centromeric (p11 to
q11) or pericentromeric (p11.2 and q11.2) regions of chromosomes
12, 13, 14, 15, 17 18 and 20. Interestingly, in this latter study
Knutsen et al [21] also found recurrent breakpoints at 17p11.2 in
6/15 cell lines.
In the present study, a high percentage of cases showed
recurrent breakpoints for chromosomes 1, 8, 17 and 20. Most
interestingly, breakpoints at chromosome 17p were preferentially
localized at the genome coordinate 20,156,497–22,975,771 bp at
17p12 (15/23 cases); in most of these cases (12/15 cases), the
breakpoint was restricted to the genome coordinate (21,769,828–
22,975,771 bp) which maps for the FAM27L gene, a gene whose
function remains to be elucidated. Whether, disruption of the
FAM27L gene may also play a role in the malignant transforma-
tion and/or the metastatic process of CRC into the liver in
addition to, inactivation of TP53 and inhibition of apoptosis
[47,48], remains to be elucidated. Nevertheless, it should be noted
that Camps et al [10] have shown a higher frequency of 17p11.2
breakpoints in CRC patients with positive (8/16) vs. negative (4/
Table 5. Primary colorectal cancer with liver metastasis
(n=23): correlation between the numerical changes detected
by each individual iFISH probe used and the CN changes
identified for the corresponding single nucleotide
polymorphisms (SNPs) through SNP array studies.
Chromosomal region identified by the
iFISH probe R
2/P-value
1p36 0.75/,0.001
1q25 0.75/,0.001
2p24 0.65/0.001
3q26 0.81/,0.001
5p15.2 0.65/0.001
6q23 0.67/,0.001
7q31 0.67/,0.001
8p22 0.81/,0.001
8q24 0.79/,0.001
9p21 0.91/,0.001
9q34 0.77/,0.001
10q23 0.68/,0.001
11q22 0.82/,0.001
12p13 0.76/,0.001
13q14 0.74/,0.001
13q34 0.78/,0.001
14q32 0.82/,0.001
15q22 0.72/,0.001
17p13 0.80/,0.001
18q21 0.75/,0.001
19q13 0.65/,0.001
20q13.2 0.80/,0.001
21q22 0.74/,0.001
22q11.2 0.83/,0.001
R
2: Coefficient of correlation.
doi:10.1371/journal.pone.0013752.t005
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previously associated with an homogeneous genetic profile defined
by a higher frequency of abnormalities of chromosomes 1p, 7, 8,
13q, 18q and 20q and an adverse clinical outcome [35,49–52].
Other recurrent chromosomal breakpoints found in our patients
were localized in the 1p12, 8p12 and 20p12.1 chromosomal
regions. Previous studies suggest that genes typically deregulated
by these chromosome breaks included the REG4 [53] and
NOTCH2 [54] genes at chromosome 1p12, EIF4EBP1 [55] and
FGFR [56] at chromosome 8p12, and the FOXA2 [57] gene at
chromosome 20p12; all these genes have been associated with the
development and progression of CRC and the metastatic process
in a variety of human cancers, including the development of liver
metastases in CRC [53–57]. Additional GEP and functional
studies as well as direct comparison of paired primary and
metastatic tumours are required to validate our findings and to
gain further insight into their role in metastatic CRC patients.
Supporting Information
Figure S1 Primary colorectal cancer with paired liver metastasis
(n=23): Identification of recurrent chromosomal breakpoint
regions for the 1p12, 8p12, 17p11.2 and 20p12.1 chromosome
regions as defined by the Affymetrix 500K SNP array genotyping
platform. Breakpoints occurred in 9 cases (39%) at the 118097448-
120939802 genome coordinate for chromosome 1 (panel A), in 8
cases (35%) at the 37770635-38405382 coordinate for chromo-
some 8 (panel B), in 15 cases (65%) at the 20156497-22975771
position for chromosome 17 (panel C) and in 9 cases (39%) at the
14921777- 16089156 genome coordinate for chromosome 20
(panel D).
Found at: doi:10.1371/journal.pone.0013752.s001 (4.70 MB TIF)
Table S1 Most frequently detected amplified regions (for .3
contiguous SNPs with average log2 copy number ratio .0.22) in
primary colorectal tumours from metastatic CRC patients
genotyped on the Affymetrix 500K SNP array platform (n=23).
Only recurrently amplified DNA copy-number regions found in at
least half of the cases, are listed.
Found at: doi:10.1371/journal.pone.0013752.s002 (0.10 MB
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